Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
US Chamber Raises Japan’s Pharma Policy as Unfair Trade Practice, Prods Federal Govt for Action
The US Chamber of Commerce has raised Japan’s pharmaceutical pricing as an “unfair trade practice” in a comment submitted to the federal government, calling for addressing the lack of transparency and predictability in the Japanese reimbursement system. The chamber particularly…
To read the full story
Related Article
- MHLW to “Listen to Industry Opinions” in Policymaking around CEA: Minister
March 13, 2025
- No Prior Talks with US Drug Makers for Deferred PMP Price Cuts: Health Minister
March 3, 2025
- Minister Touts “Balanced” Off-Year Revision after USCC Letter
February 19, 2025
- MHLW Not Yet Able to Examine Letters of Protest by US Lobbies: Minister
February 13, 2025
- US Lobbies Send Letters of Protest to Japan Embassy over Off-Year Revision, CEA
February 10, 2025
REGULATORY
- LDP Lawmakers Seek Separate Drug Pricing Measures for Inflation
July 2, 2026
- Govt’s Honebuto Draft Confirms FY2027 Off-Year Drug Price Revision
July 1, 2026
- Govt Presents Growth Strategy Draft Ahead of July Approval
July 1, 2026
- Japan Moves to Add Ceftriaxone to Economic Security List
July 1, 2026
- LDP Group Submits Honebuto Proposal, Urges Pediatric Cancer Platform
July 1, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…